

# Fludarabine (phosphate)

Catalog No: tcsc0861



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

75607-67-9

**Formula:**

$C_{10}H_{13}FN_5O_7P$

**Pathway:**

Cell Cycle/DNA Damage

**Target:**

Nucleoside Antimetabolite/Analog

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq$  100 mg/mL (273.82 mM); H<sub>2</sub>O : 5 mg/mL (13.69 mM; Need ultrasonic)

**Observed Molecular Weight:**

365.21


## Product Description

Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.

**In Vitro:**

Fludarabine phosphate significantly reduces the cell viability in a dose-dependent manner. Fludarabine phosphate exhibits no effect in all tested concentrations when combined with either PBS or control vector, ACE-GFP. Fludarabine phosphate causes a significant decrease in cell viability for 24 h after exposure to ACE-PNP when compared to PBS and ACE-GFP at concentrations of 2.5, 5 and 10  $\mu\text{g/mL}$ <sup>[2]</sup>.

**In Vivo:** F-araAMP (100 mg/kg given 15 times, 167 mg/kg given 9 times, or 250 mg/kg given 3 times, i.p.) leads to complete regressions of all tumors and cures of all mice. Parental D54 tumors (i.e. without E. coli PNP) are not sensitive to treatment with F-araAMP. Intratumoral injection of Ad/PNP followed by IT F-araAMP can elicit a substantial regressive effect on otherwise refractory solid tumors in a fashion substantially superior to viral PNP transduction followed by systemic prodrug administration<sup>[1]</sup>. The comparison of ACE-GFP/fludarabine phosphate with ACE-GFP/PBS demonstrates that fludarabine phosphate alone has no growth inhibitory activity on KU-19-19 tumors<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!